SOURCE: Broncus Technologies, Inc.

November 20, 2007 09:55 ET

Broncus Technologies, Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering

MOUNTAIN VIEW, CA--(Marketwire - November 20, 2007) - Broncus Technologies, Inc., a medical technology company focused on developing and commercializing minimally invasive medical devices for emphysema and other lung diseases, today announced the filing of a registration statement with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. All of the shares of common stock in the offering are being offered by Broncus.

Lehman Brothers Inc. and Bear, Stearns & Co. Inc. will serve as joint book-running managers for the offering, with Jefferies & Company, Inc. and RBC Capital Markets Corporation acting as co-managers. A preliminary prospectus for the offering, when available, may be obtained from Lehman Brothers Inc. c/o Broadridge Integrated Distribution Services, 1155 Long Island Avenue, Edgewood, NY 11717, by faxing a request to 631-254-7140 or by sending an email to qiana.smith@broadridge.com, or from Bear, Stearns & Co. Inc. Attention: Prospectus Department, Bear, Stearns Securities Corp., One MetroTech Center North, Brooklyn, NY 11201, by faxing a request to (347) 643-4623 or by sending an email to elopez@bear.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Broncus

Broncus is a medical technology company focused on developing and commercializing minimally invasive medical devices for emphysema and other lung diseases. Broncus has developed the Exhale emphysema product line to perform its patented treatment method called Airway Bypass, and is currently enrolling patients in its pivotal EASE Trial for the treatment of severe homogeneous emphysema.

Broncus and Exhale are trademarks of Broncus Technologies, Inc.